Article

Shortening the Biologics Clinical Timeline with a Novel Method for Generating Stable, High Producing Cell Pools and Clones

2022-12-15

Abstract excerpt

Reducing drug development timelines is an industry-wide goal to bring medicines to patients in need more quickly. This was exemplified in the COVID-19 pandemic where reducing development timelines had a direct impact on the number of lives lost to the disease. The use of drug substance produced using cell pools, as opposed to clones, has the potential to shorten development timelines. Toward this goal, we have dev...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7eb0162c-e0e3-5fed-bcb6-75d10c088079
DOI: 10.22541/au.167113298.81559773/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Shortening the Biologics Clinical Timeline with a Novel Method for Generating Stable, High Producing Cell Pools and ClonesDOI 10.22541/au.167113298.81559773/v1Read

Rapid cGMP Manufacturing of COVID-19 monoclonal antibody using stable CHO cell poolsSemantic proximity Read

Repressing expression of difficult‐to‐express recombinant proteins during the selection process increases productivity of CHO stable poolsSemantic proximity Read

When will we have a clone? An industry perspective on the typical CLD timelineSemantic proximity Read

Demonstration of a robust high cell density transient CHO platform yielding mAb titers of up to 2 g/L without medium exchangeSemantic proximity Read

Diversity in host clone performance within a <scp>C</scp> hinese hamster ovary cell lineSemantic proximity Read

Towards maximum acceleration of monoclonal antibody development: Leveraging transposase-mediated cell line generation to enable GMP manufacturing within 3 months using a stable poolSemantic proximity Read

A CHO stable pool production platform for rapid clinical development of trimeric SARS‐CoV‐2 spike subunit vaccine antigensSemantic proximity Read

Utilizing non-clonal CHO cell derived materials for preclinical studies of complex moleculesSemantic proximity Read

Bioreactor scale up and protein product quality characterization of piggyBac transposon derived CHO poolsSemantic proximity Read

Recombinant antibody-producing stable CHOK1 pool stability studySemantic proximity Read

High-Level Production of Recombinant Proteins in CHO Cells Using a Dicistronic DHFR Intron Expression VectorSemantic proximity Read

Protein production from HEK293 cell line-derived stable pools with high protein quality and quantity to support discovery researchSemantic proximity Read